Skip to main content

Table 1 Patient demographics and other baseline characteristics

From: Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

  nsNSAID (n = 219) Celecoxib (n = 55)
Age, years, mean (SD) 8.2 (4.45) 10.0 (4.09)
Sex, n (%)   
 Male 54 (24.7) 8 (14.5)
 Female 165 (75.3) 47 (85.5)
Race, n (%)   
 White 193 (88.1) 49 (89.1)
 Black 16 (7.3) 5 (9.1)
 Asian 6 (2.7) 0
 Other 4 (1.8) 1 (1.8)
Ethnicity, n (%)   
 Hispanic or Latino 19 (8.7) 2 (3.6)
 Non-Hispanic or Latino 200 (91.3) 53 (96.4)
Body mass index categories, n (%)   
 Underweight 10 (4.6) 6 (10.9)
 Healthy weight 143 (65.3) 36 (65.5)
 Overweight 38 (17.4) 8 (14.5)
 Obese 20 (9.1) 4 (7.3)
 Missing 8 (3.7) 1 (1.8)
Months since JIA diagnosis, median (range) 4.25 (0–163.0) 12.10 (0.5–173.5)
JIA category, n (%)   
 Systemic 3 (1.4) 0
 Persistent oligoarticular 119 (54.3) 27 (49.1)
 Extended oligoarticular 12 (5.5) 2 (3.6)
 Poly RF (–) 70 (32.0) 23 (41.8)
 Poly RF (+) 14 (6.4) 3 (5.5)
 Missing 1 (0.5) 0
Patients that have discontinued ≥1 NSAID in prior year,a n (%) 114 (52.1) 46 (83.6)
 AE 16 (7.3) 25 (45.5)
 Other reasons 64 (29.2) 15 (27.3)
 Lack of efficacy 40 (18.3) 10 (18.2)
 Both AE/lack of efficacy 3 (1.4) 4 (7.3)
Rheumatologic joint assessment, mean (SD)   
 Number of joints with active arthritisb 2.9 (4.1) 3.4 (5.4)
 Number of joints with swelling 2.7 (4.0) 3.1 (5.1)
 Number of joints with pain on motion/tenderness 1.7 (3.6) 2.5 (4.3)
 Number of joints with loss of motion 1.7 (3.0) 1.9 (3.2)
Childhood health assessment questionnaire, median (range)   
 Functioning (in past week)c 0.35 (0–2.5) 0.44 (0–2.5)
 Paind 0.45 (0–3.0) 0.66 (0–2.5)
 Global evaluatione 14.00 (0–87.0) 16.50 (0–97.0)
 Physician’s Global Assessment of Disease Activity,f mean (SD) 2.9 (2.2) 2.6 (2.4)
 Parent/subject assessment of overall well being,g mean (SD) 2.8 (2.5) 3.2 (2.6)
  1. aPatients discontinuing more than 1 NSAID for the same reason are only counted once in the overall summary; however, if a patient discontinued an NSAID for more than 1 reason, the patient contributes to the summary of each of those reasons.
  2. bActive arthritis is defined as swelling of the joint or, if no swelling is present, loss of motion accompanied by pain on motion or tenderness.
  3. cFunctioning can range from 0–3, where higher scores indicate more impairment.
  4. dPain can range from 0–3, where 0 = no pain and 3 = very severe pain.
  5. eGlobal evaluation can range from 0–100, where 0 = very well and 100 = very poor.
  6. fPhysician’s Global Assessment can range from 0–10, where 0 = not active and 10 = very active.
  7. gParent/subject assessment of overall well-being can range from 0–10, where 0 = very well and 10 = very poorly.
  8. Abbreviations AE: Adverse event, JIA Juvenile idiopathic arthritis, nsNSAID Nonselective nonsteroidal anti-inflammatory drug, RF Rheumatoid factor.
\